POLYTECH Health & Aesthetics GmbH, a Germany-based company involved in breast aesthetics, reconstruction, and body contouring, and the London Regenerative Institute (LRI), a clinician-led institute specialising in regenerative medicine, adipose tissue processing and translational education, announced Friday a worldwide partnership to advance the use of adipose tissue-based techniques in aesthetic and reconstructive surgery.
This partnership brings together two complementary capabilities. POLYTECH says that it contributes an established international commercial infrastructure, long-standing relationships with plastic and reconstructive surgeons, and a training model focused on hands-on education. The London Regenerative Institute contributes a clinician-led research and development environment with a focus on adipose tissue processing, regenerative protocols and structured clinical training.
Plans for the partnership include launching a portfolio, as well as physician education initiatives, workshops, and clinical training programmes.
HR HealthCare establishes charitable arm
Sobi presents phase 3 gout study results for pozdeutinurad
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
Formation Bio establishes USD600m debut fund for drug development
Ascletis reports positive US Phase II topline results for ASC30 in diabetes
MetaVia announces presentation of DA-1726 Phase 1 data at Precision Liver Symposium
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
United Therapeutics receives FDA clearance to advance inhaled PAH therapy into clinical trials
US WorldMeds acquires Orbus Therapeutics
DifGen Pharmaceuticals completes European Decentralised Procedure for Tafamidis 61 mg Capsules
Astellas and Audax Biosciences sign exclusive option and licence agreement for DAX-044
IRLAB Therapeutics receives US patent allowance for Parkinson's drug candidate IRL1117
Thor Medical signs three-year isotope supply agreement with Medicines Discovery Catapult
Enhertu wins EU approval for HER2-positive early breast cancer treatment